Skip to content

The clinical study comparing the effectiveness and safety of transmesenteric vein extrahepatic portosystemic shunt (TEPS) with endoscopic treatment for the prevention of esophagogastric variceal bleeding in portal vein thrombosis and cavernous transformation

The clinical study comparing the effectiveness and safety of transmesenteric vein extrahepatic portosystemic shunt (TEPS) with endoscopic treatment for the prevention of esophagogastric variceal bleeding in portal vein thrombosis and cavernous transformation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078491
Enrollment
Unknown
Registered
2023-12-11
Start date
2023-12-11
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

portal vein thrombosis/cavernous transformation of portal vein

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 75 years; 2. Diagnosed PVT/CTPV, confirmed EGVB based on endoscopy examination; 3. Child-Pugh score is less than10; 4. Completely or partially unobstructed SMV according to imaging examination; 5. Understand the risk associated with surgery and endoscopic treatment, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with non-variceal gastrointestinal bleeding (acute erosive gastritis, peptic ulcer, gastric cancer); 2. Previous endoscopic treatment for EGVB within the past year; 3. Previous TIPS, surgical disconnection, or other abdominal surgeries; 4. Complicated with spontaneous peritonitis that cannot be controlled by combined medical treatment; 5. Uncontrolled EGVB or stabilized for less than one week; 6. Child-Pugh score is greater than or equal to 10; 7. Complicated with infection and shock before operation that cannot tolerate invasive procedures and treatment; 8. Dysfunction of organs including heart, lung, kidney and brain, and pulmonary hypertension; 9. Liver cancer and other malignant tumors beyond Milan criteria; 10. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Uncontrolled rupture or rebleeding of esophageal and gastric varices after treatment;

Secondary

MeasureTime frame
Risk associated with surgery or endoscopic treatment;Complications associated with portal hypertension;Other adverse events;Disease burden;

Countries

China

Contacts

Public ContactHao Wu

Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University

594264513@qq.com+86 189 8060 1287

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026